SlideShare una empresa de Scribd logo
1 de 44
Descargar para leer sin conexión
www.hemas.com
Contents


• Country Overview : Key Statistics
• Hemas Group: A Snap Shot
• Our Businesses
   •   FMCG
   •   Healthcare
   •   Transportation
   •   Leisure
   •   Power
• CSR – Hemas Outreach Foundation


                                      2
Sri Lanka: Key Statistics



            Nominal GDP                                           USD 51Bn (2010)
            GDP per Capita                                        USD 2,399 (2010)
            Real GDP Growth                                       8.0% (2010)
            Inflation                                             9.8% (April 11, CCPI Y-Y change)
            Interest Rate                                         7.3 % (12-month T-bill)
            Exchange Rate                                         LKR 110/USD




                                                                                                       3
Source: CBSL, Country Report - Sri Lanka, Economist Intelligence Unit, Global Finance, Asian Tribune
Post War: A new era of opportunity


      •   Political stability post elections

      •   Economy expected to expand ~ 6.6% a year over the next 5 years

      •   Improved investor confidence: stock market performance in 2010
          ~104% (2009 ~ 125% )

      • Tourism potential: 46% growth in arrivals for 2010




                                                                                                       4
Source: CBSL, Country Report - Sri Lanka, Economist Intelligence Unit, Global Finance, Asian Tribune
HEMAS GROUP


              5
Hemas : Key Statistics

   Share Price                      Rs 47.50
   Market Capitalization            Rs 24.3Bn
   % of Total Market                0.94%
   PER                              20.1 times
   PBV                              2.7 times
   No of Shares                     512Mn
   Public Shareholding              28.05%

Rs Mn.                      10/11      09/10     Change

Group Turnover             18,067     14,997     20.5%
Group Earnings              1,210        902     34.2%
Shareholders’ Funds         8,874      7,692     15.4%
Capital Employed           14,666     12,367     18.5%
                                                          6
The Hemas Group

                          Hemas Holdings PLC

                                                      Hemas Power
FMCG   Healthcare      Leisure       Transportation                   Other
                                                       PLC (75%)

                         Serendib                       Heladhanavi   IT Network
           Pharma       Hotels PLC          GSAs
                                                           (47%)       Solutions
                          (51%)
           Hospitals
                         Diethelm          Travels      Hydro Power    Property
            (70%)
                          Travels
                           (80%)
                                          Maritime                       BPO


                                          Freight &
                                          Logistics
                                           (49%)


                                                                               7
Our Portfolio - FY10/11
                                                                                Earnings
      Turnover
                                                                                    0%
       4% 3%                                                                  16%


19%              32%
                                                                                             38%



                                                                        23%
6%

                                    Capital Employed
                                                                              4%
          36%                                                                        19%

                                         9%
                                                     18%
                                    5%




                              30%
                                                            27%


                                              10%


         FMCG    HEALTHCARE         LEISURE         POWER         TRANSPORTATION     OTHER         8
Group Revenue: 5-Year CAGR ~ 13.1%

Rs. Mn.
20,000                                                               25%
                  20%                                          20%
18,000      20%
                                                                     20%
16,000
14,000
                                                                     15%
12,000
10,000                                                               10%
                                          7%
  8,000
                                                                     5%
  6,000
  4,000
                                                                     0%
  2,000                                                 -1%

     -                                                               -5%
           2007   2008             2009         2010          2011

                        Top line               Growth

                                                                           9
Growth in EPS Expected to Rebound

Rs.
2.50                                                                                         34%   40%
                                                                                                   30%
2.00
                                                                          17%                      20%
                                           12%
1.50                                                                                               10%
                        4%                                                                         0%
1.00                                                                                               -10%
                                                                                                   -20%
0.50
                                                             -32%                                  -30%
  -                                                                                                -40%
                 2007              2008               2009               2010               2011

                                            EPS           Growth

      Comparative figures adjusted for sub division of ordinary shares in the proportion of 5:1
                                                                                                        10
ROE: Showing signs of improvement
Rs. Mn.
10,000                                                                         25%
 9,000     21.0%
                     19.4%
 8,000                                                                         20%
 7,000
 6,000                                                                    14.6% 15%
                                          11.5%
 5,000
                                                           12.3%
 4,000                                                                         10%
 3,000
 2,000                                                                         5%
 1,000
    -                                                                          0%
          2007     2008            2009             2010           2011
                    Shareholders' funds           ROE
                                                                                 11
Cash flows Vs Earnings

Rs. Mn.
2,500


2,000


1,500


1,000


  500


   -
          2007     2008         2009      2010     2011
                   Operating Cashflow   Earnings

                                                          12
Governance


• Board of Directors:
   – Four independent non- executive directors (including Chairman), one
     non-executive director, three executive directors
• Board sub committees:
   – Audit committee – Two independent non- executive directors
   – Remuneration committee - Two independent non- executive directors
• Focus on Risk Management




                                                                           13
FMCG: Overview
                                                  FMCG Market ~ 141Bn
• Hemas, No.2 in Personal Care                 11%
  category
                                                                      Food & Beverages
                                         15%
• Portfolio includes 18 popular brands                                Personal Care

                                                                      Homecare
• Market Leader in baby care, hair oil                    74%
  and men’s grooming categories

• Modern state-of-the-art production
                                                            Hemas
  factory with R&D facilities
                                                                    19%
• Island wide distribution reach          Personal Care
  ~ 80,000 outlets
                                          Food & Home Care

                                                                22%                   59%
                                          Personal Wash


                                                                                      14
FMCG: Key Brands

                                           Baby Cheramy
                                           •   Market leader in the baby care
                                               category



                                                                       Diva
Clogard                                                                •   A leading washing powder in
                                                                           the market
•   Clear USP - Clove oil




                 Kumarika
                 •   Market leader in the hair oil           Velvet
                     market
                                                             •   Toilet soap, re-launched in
                 •   4thlargest revenue generator in             December 09
                     the sector

                                                                                                   15
FMCG: 10-11 update
                                                                 Turnover
 Key Statistics              2010/11   2009/10   Growth

                                                                         32%
 Turnover (Rs. Mn)             5799     5247       11%

 Profit After Tax (Rs. Mn)     519       636       (18%)

                                                                Sector    Group

• Baby care, Fragrances, Homecare and Personal wash
  contributed positively to growth in turnover

• New taxes levied on imports and increasing raw material
  prices impacted profitability, year-on-year

• Diva commenced local manufacturing at Dankotuwa

• Re-launch of Fems, our sanitary napkin brand and the launch
  of new variants of Kumarika, our hair oil brand
                                                                               16
FMCG: Accolades for our manufacturing facility


• Gold award for the Extra Large
  Category at the CNCI ‘Achievers of
  Industrial Excellence’ Awards 2010




                                       • GOLD Award at the ‘National
                                         Productivity Award 2009/10’
                                         presented by the National
                                         Productivity Secretariat

                                                                       17
FMCG: Strategic Focus

• Consolidation of Personal care brands
• Strengthen Household and Feminine Hygiene categories
• Expand with selected categories in Bangladesh market
• Explore opportunities to expand the Foods portfolio




                                                         18
Healthcare: Overview of the Pharmaceutical business

                                                         Total Market
• Core business: distribution of
  pharmaceutical products

• Market leader with a share of                    30%

  16.4% (source: IMS)

• Represents 25 multinational                                                    60%
  pharmaceutical companies Market
                      Total                        10%


• Widest and strongest distribution
  network
                  30%
                                        Private/Retail segment - pharmacies
• Overall pharmaceutical market         Institutional segment - Private hospitals & Osu Sala
  grew by ~ 20% , in 2010, driven by
  growth in volume (Source: IMS ) 60%   Tender segment - govt. hospitals & SPC
                 10%                                                                    19
Healthcare: Overview of Hospitals
Inpatient split between                         Out Patient split between
   Govt. and Private                            Govt. and Private Hospitals
                                                                                     • 100-bed hospital in Wattala and a 50-bed
       Hospitals                                                                       hospital in Galle
                13%
                                                40%
                                                                                     • Operations of Wattala commenced in
   87%                                                                         60%     December 2008 and Galle in March 2009

                                                                                     • Dedicated to provide patient centric
      Private    Public                                 Private       Public
                                                                                       medical care at affordable prices

                      Western Province                                               • Certification pending for ACHSI
                 Private Sector Revenue Split
                                                                                       accreditation
                                   6%
                                                 22%

                      23%                                                            • ISO 15189 awarded for laboratory services

                1%
                                                      24%
                                                                                     • Tie-ups with institutions providing tertiary
                          12%
                                                                                       education in nursing
                                    12%
         Durdans                Nawaloka              Asiri Medical
         Asiri Surgical         Asiri Central         Lanka Hospitals                • 3rd hospital at Battaramulla, to commence
         Hemas                                                                         construction                         20
Healthcare: Our Hospitals at Wattala & Galle

                                       Wattala
                                       • 100-bed state-of-the-art hospital with 10-bed
                                         ICU & NICU
                                       • Approximately 130 consultants practice on a
                                         visiting basis
                                       • Modern facilities including 20 consultation
                                         chambers and 5 operating theaters
                                       • Fixed priced health packages to ensure
                                         affordability & predictability



Galle
• 50-bed hospital with ICU
• Focus on providing health services
  to the fast growing suburban
  community
                                                                                     21
Healthcare: 10-11 update
                                                                         Turnover

     Key Statistics              2010/11   2009/10   Growth
                                                                                 36%
     Turnover (Rs. Mn)           6514       5049      29%

     Profit After Tax (Rs. Mn)    232         68      239%

                                                                        Sector    Group



•   Hospital sector showed a Turnover growth of 45% for the year
•   Wattala Hospital achieved cash break-even position in May 2010, 18 months after
    commencement
•   Growing consumer confidence in our Hospitals reflected by a 38% increase in
    surgeries
•   Pharmaceutical business continued to maintain its position as market leader,
    recording a turnover growth of 24%


                                                                                       22
Healthcare: Hospital laboratory expands to open in Ragama

  •   The new lab is equipped with
      automated biochemistry and
      hematology analyzers, providing
      speedy and accurate laboratory test
      reports round the clock

  •   Lab records 110 blood tests per day




                                            •   The lab also provides ECG service,
                                                Channeling & information services
                                                and CT & MRI referral services for
                                                Hemas Hospital Wattala



                                                                                     23
Healthcare: Hospital Expansion Plan

• Two 50 bed hospitals in Battaramulla
  and Ratmalana
                                                  Battaramulla

• Approximate date for commencement
  of construction - May 2011 (1st
  Hospital in Battaramulla)
                                                  Colombo

• Period of construction estimated at 12
                                                  South


  months

• Commercial operations expected to
  start within 3 months following
  completion

• Estimated project cost per new
  hospital – Rs 950 Mn
                                                        24
Healthcare: Strategic Focus

• Expansion plans for OTC business
• Looking to attract new agencies and consolidate market position in
  the Pharmaceutical market
• Stabilize operations in existing hospitals and expand into identified
  key locations & sites




                                                                          25
Transportation: Overview

       • Sector operates in the Aviation, Maritime and
         integrated logistics space

       • Market leader in aviation, representing two of
         the largest airlines, Emirates (EK) and Malaysia
         Airlines (MAS)

       • Maritime arm represents a Singaporean feeder
         agency, Far Shipping

       • Entered the asset ownership business space by
         acquiring a 17% stake in MSL

       • Sector entered into an agreement with NCGB
         India and Lanka IOC to provide Maritime Support
         Services

       • Retains interest in Courier and the Freight
         Forwarding industry
                                                         26
Transportation: 10-11 Update
                                                                             Turnover
                                                                                 4%
     Key Statistics              2010/11   2009/10    Growth

     Turnover (Rs. Mn)            734        664       11%

     Profit After Tax (Rs. Mn)    224        181       24%

                                                                            Sector    Group



•   Growth in passenger sales drives sector performance during the year

•   GSA passenger and cargo sales have shown a growth of 38% and 21% respectively,
    year-on-year
•   Hemas was appointed as the GSA in Sri Lanka for Ukraine International Airlines during
    the year
•   Positive sentiment surrounding maritime industry contributes growth in Far Shipping
    sales

•   Far shipping operations expands to Chittagong , Bangladesh                           27
Transportation: Strategic Focus

• Consolidate the market leadership position in the Aviation business
• Look out for opportunities in the local aviation industry
• Opportunities to expand the Maritime and Ports related business




                                                                        28
Leisure: Overview
     • Hemas owns 51% stake in Serendib Hotels, a public listed hotels group
     • Serendib Group consists 3 hotels located in Bentota, Negombo, Sigiriya, and
       manages and owns 19.9% of a fourth hotel in Kalutara with a room strength of 105
     • Hemas owns 2 undeveloped properties in Kandy and Tangalle
     • Strategic alliance with Minor International, Thailand
     • Diethelm Travels, a strategic partnership with Diethelm Group, recently started
       operations in Maldives



                                               Kuchchaveli*
           Hotel Sigiriya,
           Sigiriya


           Hotel
                                                   Mowbray,
           Dolphin,
                                                     Kandy
           Waikkal

                                                    Peace Haven,
           Serendib                                     Tangalle
           Hotel,
           Bentota

                                                                                          29
Source: SLTDA                *To be acquired
Leisure: Market Statistics of Serendib Hotels



                        Voting      Non Voting
Share Price             Rs 30.80    Rs 18.70
Market Capitalization   Rs 1.9Bn    Rs 0.5Bn
% of Total Market       0.07%       0.02%
PER                     16.0times   4.6times
PBV                     1.5times    0.5times
No of Shares            60.4Mn      28.8Mn
Public Shareholding     29.66%      26.64%




                                                 30
Leisure: 10-11 Update
                                                                               Turnover
                                                                                    6%
    Key Statistics              2010/11   2009/10     Growth

    Turnover (Rs. Mn)             1035      752        38%

    Profit After Tax (Rs. Mn)      122       33       263%
                                                                           Sector        Group




•   Our hotels continued to benefit from the positive outlook of the country
•   Hotels recorded an average occupancy in excess 80%, for the year under review
•   Dolphin Hotel was refurbished at a cost of Rs. 530Mn and reopened in October 2010
•   Kani Lanka Resort and Spa was acquired by Hemas through Serendib Hotels PLC



                                                                                            31
Leisure: Dolphin Hotel upgraded to 4 star

• Reopened in October 2010
• Refurbishment cost - Rs. 530Mn




                                                      32
Leisure : Twin Experience of PLAY & PAUSE at Dolphin . . .




                                                        33
Leisure: Acquisition of Kani Lanka

                                             •   A 150 key luxury hotel is being developed
                                                 adjacent to the current hotel and will be
                                                 the first – ever ‘Anantara‘ branded resort
                                                 in Sri Lanka




•   Hemas acquired a 19.9% stake in Kani
    Lanka Resort and Spa, through its
    subsidiary Serendib Hotels PLC

•   Minor International PLC, our strategic
    partner, acquired the remaining 80.1%

•   The hotel is being managed by Serendib
    Leisure Management Limited

                                                                                        34
Leisure: Strategic Focus

• Refurbishment and repositioning of Hotel Serendib - construction to
  begin in May 2011
• Development of existing land banks, Peace Haven and Mowbray
• Strategic investments with Minor to develop the Anantara brand




                                                                   35
Power: Overview

                                          • 100MW thermal power plant: a joint
                                            venture with a 10 year PPA expiring in
                                            2014
                                          •    Hydro power plants with operational
                                              capacities of 2.0MW and 2.6MW
                                          • 2.4MW hydro power plant under
                                            construction
                                          • Hemas Power was listed in Sep 09, and
Energy Demand Vs Generation Requirement
                                            raised Rs. 626Mn for new investments
              in Sri Lanka
                                          • Electricity demand to grow at a CAGR
                                            of 8.6% over the long-term in Sri Lanka
                                          • Long-Term Generation Plan of CEB
                                            estimates electricity demand to
                                            increase by 5,430MW by 2022

                                                                                36
Power: Key Statistics
   Share Price                      Rs 35.80
   Market Capitalization            Rs 4.5Bn
   % of Total Market                0.17 %
   PER                              10.9 times
   PBV                              1.3 times
   No of Shares                     125Mn
   Public Shareholding              24.93%

                           10/11             09/10   Growth
Group Turnover           Rs 3.4Bn       Rs 2.9Bn      19%
Group Earnings           Rs 426Mn       Rs 244Mn      75%
Shareholders’ Funds      Rs 2.9Bn       Rs 2.5Bn      17%
Capital Employed         Rs 4.4Bn       Rs 3.7Bn      17%
                                                              37
Power: 10-11 Update
                                                                Turnover
    Key Statistics              2010/11     2009/10   Growth
                                                                        19%
    Turnover (Rs. Mn)            3,412      2,867        19%

    Profit After Tax (Rs. Mn)     426        244         75%

                                                               Sector     Group


•   Heladhanavi continues to be the largest contributor to
    group profits
•   Hydro power contribution to sector profits grow to
    45% in comparison to 25% in 09/10
•   Sector finance costs show significant reduction due to
    refinancing of working capital at Heladhanavi
•   Hemas contributed ~ 7% to the national grid this year
•   Magal Ganga set to complete in September 2011
                                                                              38
Power: Strategic Focus

• Development of on-going mini-hydro projects
• Looking to enter non-conventional renewable energy space – Bio
  mass & wind energy
• Explore overseas investments opportunities




                                                                   39
CSR: Hemas Outreach Foundation




                                 40
CSR: Our Objectives

1.   Focus on Early Childhood Care and Development (ECCD) of young
     children through pre- schools

2.   Training of pre-school teachers

3.   Empower community led social development through island wide
     parental awareness programs

4.   Improve children’s recreational facilities in disadvantaged communities

5.   Improve child protection legislation and provide publicity for children’s
     issues

6.   Sustaining the Menik Farm temporary preschools and play areas



                                                                                 41
CSR: Our activities this year . . .

• 33 Piyawara model pre-schools are being monitored and sustained by
  Hemas Outreach Foundation

• Opened first ever model pre-school in the Northern Region in Jaffna in
  January 2011

• Set up pre-schools and play areas in post war relief villages in Vavuniya

• Set up a special school for children with Down’s Syndrome in Hambantota
  area - 42 children are being rehabilitated

• Conducted residential training programs for pre-school teachers

• Weekly TV programme on Nugasevana to educate young mothers on early
  childhood development


                                                                              42
In conclusion . . .

• All sectors in the Group are well placed to benefit from expected
  economic growth
• Growth of the middle class segment to drive growth in FMCG and
  Healthcare industries
• Major investments in the medium term to be in Hospitals, Hotels and
  Power
• Exploring opportunities to enter new categories in the FMCG market




                                                                        43
Investor Relations Contact:

                       Malinga Arsakularatne
                           Chief Financial Officer

                    +94 11 4731728 / +94 77 2233642
                          malinga@hemas.com



CONFIDENTIALITY AGREEMENT:
Any confidentiality information disclosed in this presentation shall be used by the
receiving party exclusively for the purposes of fulfilling the receiving party’s
obligation and for no other purpose except with the consent of the disclosing party.

                                                                                  44

Más contenido relacionado

La actualidad más candente

Hemas Holdings PLC - Investor Presentation Q1 2013/14
Hemas Holdings PLC - Investor Presentation Q1 2013/14Hemas Holdings PLC - Investor Presentation Q1 2013/14
Hemas Holdings PLC - Investor Presentation Q1 2013/14HEMAS HOLDINGS PLC
 
Hemas Holdings PLC Investor Presentation Q3 - 2013/14
Hemas Holdings PLC Investor Presentation Q3 - 2013/14Hemas Holdings PLC Investor Presentation Q3 - 2013/14
Hemas Holdings PLC Investor Presentation Q3 - 2013/14HEMAS HOLDINGS PLC
 
Hemas Holdings PLC investor presentation - Q2 2016/17
Hemas Holdings PLC investor presentation - Q2 2016/17Hemas Holdings PLC investor presentation - Q2 2016/17
Hemas Holdings PLC investor presentation - Q2 2016/17HEMAS HOLDINGS PLC
 
Hemas Holdings PLC Investor Presentation Q2 2017/18
Hemas Holdings PLC Investor Presentation Q2 2017/18 Hemas Holdings PLC Investor Presentation Q2 2017/18
Hemas Holdings PLC Investor Presentation Q2 2017/18 HEMAS HOLDINGS PLC
 
Hemas Holdings PLC Investor Presentation Q4 2017/18
Hemas Holdings PLC Investor Presentation Q4 2017/18Hemas Holdings PLC Investor Presentation Q4 2017/18
Hemas Holdings PLC Investor Presentation Q4 2017/18HEMAS HOLDINGS PLC
 
Hemas Holdings PLC Investor Presentation Q2 2018/19
Hemas Holdings PLC Investor Presentation Q2 2018/19Hemas Holdings PLC Investor Presentation Q2 2018/19
Hemas Holdings PLC Investor Presentation Q2 2018/19HEMAS HOLDINGS PLC
 
Hemas Holdings PLC Investor Presentation Q1 2017/18
Hemas Holdings PLC Investor Presentation Q1 2017/18 Hemas Holdings PLC Investor Presentation Q1 2017/18
Hemas Holdings PLC Investor Presentation Q1 2017/18 HEMAS HOLDINGS PLC
 
Hemas Holdings PLC Investor Presentation Q1 2018/19
Hemas Holdings PLC Investor Presentation Q1 2018/19Hemas Holdings PLC Investor Presentation Q1 2018/19
Hemas Holdings PLC Investor Presentation Q1 2018/19HEMAS HOLDINGS PLC
 
Hemas Holdings PLC Investor Presentation Q3 2016-17
Hemas Holdings PLC Investor Presentation Q3 2016-17Hemas Holdings PLC Investor Presentation Q3 2016-17
Hemas Holdings PLC Investor Presentation Q3 2016-17HEMAS HOLDINGS PLC
 
Hemas Sustainability Report 201415- FINAL
Hemas Sustainability Report 201415- FINALHemas Sustainability Report 201415- FINAL
Hemas Sustainability Report 201415- FINALSudashini Christopher
 
Hemas Holdings PLC Investor Presentation Q3 2017/18
Hemas Holdings PLC Investor Presentation Q3 2017/18Hemas Holdings PLC Investor Presentation Q3 2017/18
Hemas Holdings PLC Investor Presentation Q3 2017/18HEMAS HOLDINGS PLC
 
Hemas Holdings PLC Investor Presentation Q3 2018/19
Hemas Holdings PLC Investor Presentation Q3 2018/19Hemas Holdings PLC Investor Presentation Q3 2018/19
Hemas Holdings PLC Investor Presentation Q3 2018/19HEMAS HOLDINGS PLC
 
KMLOONG – Fundamental Analysis FY15
KMLOONG – Fundamental Analysis FY15KMLOONG – Fundamental Analysis FY15
KMLOONG – Fundamental Analysis FY15lcchong76
 
Bursa – Fundamental Analysis FY15
Bursa – Fundamental Analysis FY15Bursa – Fundamental Analysis FY15
Bursa – Fundamental Analysis FY15lcchong76
 
GAB – Fundamental Analysis FY15
GAB – Fundamental Analysis FY15GAB – Fundamental Analysis FY15
GAB – Fundamental Analysis FY15lcchong76
 
PADINI – Fundamental Analysis FY15
PADINI – Fundamental Analysis FY15PADINI – Fundamental Analysis FY15
PADINI – Fundamental Analysis FY15lcchong76
 
DIGI – Fundamental Analysis FY15
DIGI – Fundamental Analysis FY15DIGI – Fundamental Analysis FY15
DIGI – Fundamental Analysis FY15lcchong76
 
CARLSBG – Fundamental Analysis FY14
CARLSBG – Fundamental Analysis FY14CARLSBG – Fundamental Analysis FY14
CARLSBG – Fundamental Analysis FY14lcchong76
 
Tenaga – Fundamental Analysis FY15
Tenaga – Fundamental Analysis FY15Tenaga – Fundamental Analysis FY15
Tenaga – Fundamental Analysis FY15lcchong76
 
SWOT Analysis - Hemas holdings PLC Sri Lanka
SWOT Analysis - Hemas holdings PLC Sri Lanka SWOT Analysis - Hemas holdings PLC Sri Lanka
SWOT Analysis - Hemas holdings PLC Sri Lanka mnikzaad
 

La actualidad más candente (20)

Hemas Holdings PLC - Investor Presentation Q1 2013/14
Hemas Holdings PLC - Investor Presentation Q1 2013/14Hemas Holdings PLC - Investor Presentation Q1 2013/14
Hemas Holdings PLC - Investor Presentation Q1 2013/14
 
Hemas Holdings PLC Investor Presentation Q3 - 2013/14
Hemas Holdings PLC Investor Presentation Q3 - 2013/14Hemas Holdings PLC Investor Presentation Q3 - 2013/14
Hemas Holdings PLC Investor Presentation Q3 - 2013/14
 
Hemas Holdings PLC investor presentation - Q2 2016/17
Hemas Holdings PLC investor presentation - Q2 2016/17Hemas Holdings PLC investor presentation - Q2 2016/17
Hemas Holdings PLC investor presentation - Q2 2016/17
 
Hemas Holdings PLC Investor Presentation Q2 2017/18
Hemas Holdings PLC Investor Presentation Q2 2017/18 Hemas Holdings PLC Investor Presentation Q2 2017/18
Hemas Holdings PLC Investor Presentation Q2 2017/18
 
Hemas Holdings PLC Investor Presentation Q4 2017/18
Hemas Holdings PLC Investor Presentation Q4 2017/18Hemas Holdings PLC Investor Presentation Q4 2017/18
Hemas Holdings PLC Investor Presentation Q4 2017/18
 
Hemas Holdings PLC Investor Presentation Q2 2018/19
Hemas Holdings PLC Investor Presentation Q2 2018/19Hemas Holdings PLC Investor Presentation Q2 2018/19
Hemas Holdings PLC Investor Presentation Q2 2018/19
 
Hemas Holdings PLC Investor Presentation Q1 2017/18
Hemas Holdings PLC Investor Presentation Q1 2017/18 Hemas Holdings PLC Investor Presentation Q1 2017/18
Hemas Holdings PLC Investor Presentation Q1 2017/18
 
Hemas Holdings PLC Investor Presentation Q1 2018/19
Hemas Holdings PLC Investor Presentation Q1 2018/19Hemas Holdings PLC Investor Presentation Q1 2018/19
Hemas Holdings PLC Investor Presentation Q1 2018/19
 
Hemas Holdings PLC Investor Presentation Q3 2016-17
Hemas Holdings PLC Investor Presentation Q3 2016-17Hemas Holdings PLC Investor Presentation Q3 2016-17
Hemas Holdings PLC Investor Presentation Q3 2016-17
 
Hemas Sustainability Report 201415- FINAL
Hemas Sustainability Report 201415- FINALHemas Sustainability Report 201415- FINAL
Hemas Sustainability Report 201415- FINAL
 
Hemas Holdings PLC Investor Presentation Q3 2017/18
Hemas Holdings PLC Investor Presentation Q3 2017/18Hemas Holdings PLC Investor Presentation Q3 2017/18
Hemas Holdings PLC Investor Presentation Q3 2017/18
 
Hemas Holdings PLC Investor Presentation Q3 2018/19
Hemas Holdings PLC Investor Presentation Q3 2018/19Hemas Holdings PLC Investor Presentation Q3 2018/19
Hemas Holdings PLC Investor Presentation Q3 2018/19
 
KMLOONG – Fundamental Analysis FY15
KMLOONG – Fundamental Analysis FY15KMLOONG – Fundamental Analysis FY15
KMLOONG – Fundamental Analysis FY15
 
Bursa – Fundamental Analysis FY15
Bursa – Fundamental Analysis FY15Bursa – Fundamental Analysis FY15
Bursa – Fundamental Analysis FY15
 
GAB – Fundamental Analysis FY15
GAB – Fundamental Analysis FY15GAB – Fundamental Analysis FY15
GAB – Fundamental Analysis FY15
 
PADINI – Fundamental Analysis FY15
PADINI – Fundamental Analysis FY15PADINI – Fundamental Analysis FY15
PADINI – Fundamental Analysis FY15
 
DIGI – Fundamental Analysis FY15
DIGI – Fundamental Analysis FY15DIGI – Fundamental Analysis FY15
DIGI – Fundamental Analysis FY15
 
CARLSBG – Fundamental Analysis FY14
CARLSBG – Fundamental Analysis FY14CARLSBG – Fundamental Analysis FY14
CARLSBG – Fundamental Analysis FY14
 
Tenaga – Fundamental Analysis FY15
Tenaga – Fundamental Analysis FY15Tenaga – Fundamental Analysis FY15
Tenaga – Fundamental Analysis FY15
 
SWOT Analysis - Hemas holdings PLC Sri Lanka
SWOT Analysis - Hemas holdings PLC Sri Lanka SWOT Analysis - Hemas holdings PLC Sri Lanka
SWOT Analysis - Hemas holdings PLC Sri Lanka
 

Similar a Hemas investor presentation june 2011

Sri Lanka Stock Market Quarterly earnings update sep 2011
Sri Lanka Stock Market Quarterly earnings update sep 2011Sri Lanka Stock Market Quarterly earnings update sep 2011
Sri Lanka Stock Market Quarterly earnings update sep 2011Ishara Gamage
 
dover JPMorgan_060308
dover JPMorgan_060308dover JPMorgan_060308
dover JPMorgan_060308finance30
 
dover JPMorgan_060308
dover JPMorgan_060308dover JPMorgan_060308
dover JPMorgan_060308finance30
 
dover Wachovia_100608
dover Wachovia_100608dover Wachovia_100608
dover Wachovia_100608finance30
 
dover Wachovia_100608
dover Wachovia_100608dover Wachovia_100608
dover Wachovia_100608finance30
 
Report Marketing Networking - 24.10.12
Report Marketing Networking - 24.10.12Report Marketing Networking - 24.10.12
Report Marketing Networking - 24.10.12KingBee Media
 
HENRY SCHEIN 2008IRPresentation_Final
HENRY SCHEIN 2008IRPresentation_FinalHENRY SCHEIN 2008IRPresentation_Final
HENRY SCHEIN 2008IRPresentation_Finalfinance35
 
dover BairdRoadshow
dover BairdRoadshowdover BairdRoadshow
dover BairdRoadshowfinance30
 
dover BairdRoadshow
dover BairdRoadshowdover BairdRoadshow
dover BairdRoadshowfinance30
 
CSX_Corp_-_Citi_Conf_11.14.06-REF23362
CSX_Corp_-_Citi_Conf_11.14.06-REF23362CSX_Corp_-_Citi_Conf_11.14.06-REF23362
CSX_Corp_-_Citi_Conf_11.14.06-REF23362finance27
 
CSX_Corp_-_Citi_Conf_11.14.06-REF23362
CSX_Corp_-_Citi_Conf_11.14.06-REF23362CSX_Corp_-_Citi_Conf_11.14.06-REF23362
CSX_Corp_-_Citi_Conf_11.14.06-REF23362finance27
 
Third Quarter Results FY 2010-11:Investor Release
Third Quarter Results FY 2010-11:Investor Release Third Quarter Results FY 2010-11:Investor Release
Third Quarter Results FY 2010-11:Investor Release Semalytix
 
Hclt q3-2011-jfm'11-ir release
Hclt q3-2011-jfm'11-ir releaseHclt q3-2011-jfm'11-ir release
Hclt q3-2011-jfm'11-ir releaseanvithanet
 
Ángel Ron: Competir en tiempo de crisis: un entorno desafiante para los banco...
Ángel Ron: Competir en tiempo de crisis: un entorno desafiante para los banco...Ángel Ron: Competir en tiempo de crisis: un entorno desafiante para los banco...
Ángel Ron: Competir en tiempo de crisis: un entorno desafiante para los banco...Banco Popular
 

Similar a Hemas investor presentation june 2011 (20)

3 q08
3 q083 q08
3 q08
 
Pepperdine cost of capital national summit 10 18 2011
Pepperdine cost of capital national summit 10 18 2011Pepperdine cost of capital national summit 10 18 2011
Pepperdine cost of capital national summit 10 18 2011
 
Pepperdine cost of capital national summit 10 18 2011
Pepperdine cost of capital national summit 10 18 2011Pepperdine cost of capital national summit 10 18 2011
Pepperdine cost of capital national summit 10 18 2011
 
Pepperdine cost of capital national summit 10 18 2011
Pepperdine cost of capital national summit 10 18 2011Pepperdine cost of capital national summit 10 18 2011
Pepperdine cost of capital national summit 10 18 2011
 
Sri Lanka Stock Market Quarterly earnings update sep 2011
Sri Lanka Stock Market Quarterly earnings update sep 2011Sri Lanka Stock Market Quarterly earnings update sep 2011
Sri Lanka Stock Market Quarterly earnings update sep 2011
 
IBM Business Perspective
IBM Business PerspectiveIBM Business Perspective
IBM Business Perspective
 
dover JPMorgan_060308
dover JPMorgan_060308dover JPMorgan_060308
dover JPMorgan_060308
 
dover JPMorgan_060308
dover JPMorgan_060308dover JPMorgan_060308
dover JPMorgan_060308
 
dover Wachovia_100608
dover Wachovia_100608dover Wachovia_100608
dover Wachovia_100608
 
dover Wachovia_100608
dover Wachovia_100608dover Wachovia_100608
dover Wachovia_100608
 
Report Marketing Networking - 24.10.12
Report Marketing Networking - 24.10.12Report Marketing Networking - 24.10.12
Report Marketing Networking - 24.10.12
 
HENRY SCHEIN 2008IRPresentation_Final
HENRY SCHEIN 2008IRPresentation_FinalHENRY SCHEIN 2008IRPresentation_Final
HENRY SCHEIN 2008IRPresentation_Final
 
dover BairdRoadshow
dover BairdRoadshowdover BairdRoadshow
dover BairdRoadshow
 
dover BairdRoadshow
dover BairdRoadshowdover BairdRoadshow
dover BairdRoadshow
 
CSX_Corp_-_Citi_Conf_11.14.06-REF23362
CSX_Corp_-_Citi_Conf_11.14.06-REF23362CSX_Corp_-_Citi_Conf_11.14.06-REF23362
CSX_Corp_-_Citi_Conf_11.14.06-REF23362
 
CSX_Corp_-_Citi_Conf_11.14.06-REF23362
CSX_Corp_-_Citi_Conf_11.14.06-REF23362CSX_Corp_-_Citi_Conf_11.14.06-REF23362
CSX_Corp_-_Citi_Conf_11.14.06-REF23362
 
Third Quarter Results FY 2010-11:Investor Release
Third Quarter Results FY 2010-11:Investor Release Third Quarter Results FY 2010-11:Investor Release
Third Quarter Results FY 2010-11:Investor Release
 
Hclt q3-2011-jfm'11-ir release
Hclt q3-2011-jfm'11-ir releaseHclt q3-2011-jfm'11-ir release
Hclt q3-2011-jfm'11-ir release
 
Ángel Ron: Competir en tiempo de crisis: un entorno desafiante para los banco...
Ángel Ron: Competir en tiempo de crisis: un entorno desafiante para los banco...Ángel Ron: Competir en tiempo de crisis: un entorno desafiante para los banco...
Ángel Ron: Competir en tiempo de crisis: un entorno desafiante para los banco...
 
Hcs 영문
Hcs 영문Hcs 영문
Hcs 영문
 

Hemas investor presentation june 2011

  • 2. Contents • Country Overview : Key Statistics • Hemas Group: A Snap Shot • Our Businesses • FMCG • Healthcare • Transportation • Leisure • Power • CSR – Hemas Outreach Foundation 2
  • 3. Sri Lanka: Key Statistics Nominal GDP USD 51Bn (2010) GDP per Capita USD 2,399 (2010) Real GDP Growth 8.0% (2010) Inflation 9.8% (April 11, CCPI Y-Y change) Interest Rate 7.3 % (12-month T-bill) Exchange Rate LKR 110/USD 3 Source: CBSL, Country Report - Sri Lanka, Economist Intelligence Unit, Global Finance, Asian Tribune
  • 4. Post War: A new era of opportunity • Political stability post elections • Economy expected to expand ~ 6.6% a year over the next 5 years • Improved investor confidence: stock market performance in 2010 ~104% (2009 ~ 125% ) • Tourism potential: 46% growth in arrivals for 2010 4 Source: CBSL, Country Report - Sri Lanka, Economist Intelligence Unit, Global Finance, Asian Tribune
  • 6. Hemas : Key Statistics Share Price Rs 47.50 Market Capitalization Rs 24.3Bn % of Total Market 0.94% PER 20.1 times PBV 2.7 times No of Shares 512Mn Public Shareholding 28.05% Rs Mn. 10/11 09/10 Change Group Turnover 18,067 14,997 20.5% Group Earnings 1,210 902 34.2% Shareholders’ Funds 8,874 7,692 15.4% Capital Employed 14,666 12,367 18.5% 6
  • 7. The Hemas Group Hemas Holdings PLC Hemas Power FMCG Healthcare Leisure Transportation Other PLC (75%) Serendib Heladhanavi IT Network Pharma Hotels PLC GSAs (47%) Solutions (51%) Hospitals Diethelm Travels Hydro Power Property (70%) Travels (80%) Maritime BPO Freight & Logistics (49%) 7
  • 8. Our Portfolio - FY10/11 Earnings Turnover 0% 4% 3% 16% 19% 32% 38% 23% 6% Capital Employed 4% 36% 19% 9% 18% 5% 30% 27% 10% FMCG HEALTHCARE LEISURE POWER TRANSPORTATION OTHER 8
  • 9. Group Revenue: 5-Year CAGR ~ 13.1% Rs. Mn. 20,000 25% 20% 20% 18,000 20% 20% 16,000 14,000 15% 12,000 10,000 10% 7% 8,000 5% 6,000 4,000 0% 2,000 -1% - -5% 2007 2008 2009 2010 2011 Top line Growth 9
  • 10. Growth in EPS Expected to Rebound Rs. 2.50 34% 40% 30% 2.00 17% 20% 12% 1.50 10% 4% 0% 1.00 -10% -20% 0.50 -32% -30% - -40% 2007 2008 2009 2010 2011 EPS Growth Comparative figures adjusted for sub division of ordinary shares in the proportion of 5:1 10
  • 11. ROE: Showing signs of improvement Rs. Mn. 10,000 25% 9,000 21.0% 19.4% 8,000 20% 7,000 6,000 14.6% 15% 11.5% 5,000 12.3% 4,000 10% 3,000 2,000 5% 1,000 - 0% 2007 2008 2009 2010 2011 Shareholders' funds ROE 11
  • 12. Cash flows Vs Earnings Rs. Mn. 2,500 2,000 1,500 1,000 500 - 2007 2008 2009 2010 2011 Operating Cashflow Earnings 12
  • 13. Governance • Board of Directors: – Four independent non- executive directors (including Chairman), one non-executive director, three executive directors • Board sub committees: – Audit committee – Two independent non- executive directors – Remuneration committee - Two independent non- executive directors • Focus on Risk Management 13
  • 14. FMCG: Overview FMCG Market ~ 141Bn • Hemas, No.2 in Personal Care 11% category Food & Beverages 15% • Portfolio includes 18 popular brands Personal Care Homecare • Market Leader in baby care, hair oil 74% and men’s grooming categories • Modern state-of-the-art production Hemas factory with R&D facilities 19% • Island wide distribution reach Personal Care ~ 80,000 outlets Food & Home Care 22% 59% Personal Wash 14
  • 15. FMCG: Key Brands Baby Cheramy • Market leader in the baby care category Diva Clogard • A leading washing powder in the market • Clear USP - Clove oil Kumarika • Market leader in the hair oil Velvet market • Toilet soap, re-launched in • 4thlargest revenue generator in December 09 the sector 15
  • 16. FMCG: 10-11 update Turnover Key Statistics 2010/11 2009/10 Growth 32% Turnover (Rs. Mn) 5799 5247 11% Profit After Tax (Rs. Mn) 519 636 (18%) Sector Group • Baby care, Fragrances, Homecare and Personal wash contributed positively to growth in turnover • New taxes levied on imports and increasing raw material prices impacted profitability, year-on-year • Diva commenced local manufacturing at Dankotuwa • Re-launch of Fems, our sanitary napkin brand and the launch of new variants of Kumarika, our hair oil brand 16
  • 17. FMCG: Accolades for our manufacturing facility • Gold award for the Extra Large Category at the CNCI ‘Achievers of Industrial Excellence’ Awards 2010 • GOLD Award at the ‘National Productivity Award 2009/10’ presented by the National Productivity Secretariat 17
  • 18. FMCG: Strategic Focus • Consolidation of Personal care brands • Strengthen Household and Feminine Hygiene categories • Expand with selected categories in Bangladesh market • Explore opportunities to expand the Foods portfolio 18
  • 19. Healthcare: Overview of the Pharmaceutical business Total Market • Core business: distribution of pharmaceutical products • Market leader with a share of 30% 16.4% (source: IMS) • Represents 25 multinational 60% pharmaceutical companies Market Total 10% • Widest and strongest distribution network 30% Private/Retail segment - pharmacies • Overall pharmaceutical market Institutional segment - Private hospitals & Osu Sala grew by ~ 20% , in 2010, driven by growth in volume (Source: IMS ) 60% Tender segment - govt. hospitals & SPC 10% 19
  • 20. Healthcare: Overview of Hospitals Inpatient split between Out Patient split between Govt. and Private Govt. and Private Hospitals • 100-bed hospital in Wattala and a 50-bed Hospitals hospital in Galle 13% 40% • Operations of Wattala commenced in 87% 60% December 2008 and Galle in March 2009 • Dedicated to provide patient centric Private Public Private Public medical care at affordable prices Western Province • Certification pending for ACHSI Private Sector Revenue Split accreditation 6% 22% 23% • ISO 15189 awarded for laboratory services 1% 24% • Tie-ups with institutions providing tertiary 12% education in nursing 12% Durdans Nawaloka Asiri Medical Asiri Surgical Asiri Central Lanka Hospitals • 3rd hospital at Battaramulla, to commence Hemas construction 20
  • 21. Healthcare: Our Hospitals at Wattala & Galle Wattala • 100-bed state-of-the-art hospital with 10-bed ICU & NICU • Approximately 130 consultants practice on a visiting basis • Modern facilities including 20 consultation chambers and 5 operating theaters • Fixed priced health packages to ensure affordability & predictability Galle • 50-bed hospital with ICU • Focus on providing health services to the fast growing suburban community 21
  • 22. Healthcare: 10-11 update Turnover Key Statistics 2010/11 2009/10 Growth 36% Turnover (Rs. Mn) 6514 5049 29% Profit After Tax (Rs. Mn) 232 68 239% Sector Group • Hospital sector showed a Turnover growth of 45% for the year • Wattala Hospital achieved cash break-even position in May 2010, 18 months after commencement • Growing consumer confidence in our Hospitals reflected by a 38% increase in surgeries • Pharmaceutical business continued to maintain its position as market leader, recording a turnover growth of 24% 22
  • 23. Healthcare: Hospital laboratory expands to open in Ragama • The new lab is equipped with automated biochemistry and hematology analyzers, providing speedy and accurate laboratory test reports round the clock • Lab records 110 blood tests per day • The lab also provides ECG service, Channeling & information services and CT & MRI referral services for Hemas Hospital Wattala 23
  • 24. Healthcare: Hospital Expansion Plan • Two 50 bed hospitals in Battaramulla and Ratmalana Battaramulla • Approximate date for commencement of construction - May 2011 (1st Hospital in Battaramulla) Colombo • Period of construction estimated at 12 South months • Commercial operations expected to start within 3 months following completion • Estimated project cost per new hospital – Rs 950 Mn 24
  • 25. Healthcare: Strategic Focus • Expansion plans for OTC business • Looking to attract new agencies and consolidate market position in the Pharmaceutical market • Stabilize operations in existing hospitals and expand into identified key locations & sites 25
  • 26. Transportation: Overview • Sector operates in the Aviation, Maritime and integrated logistics space • Market leader in aviation, representing two of the largest airlines, Emirates (EK) and Malaysia Airlines (MAS) • Maritime arm represents a Singaporean feeder agency, Far Shipping • Entered the asset ownership business space by acquiring a 17% stake in MSL • Sector entered into an agreement with NCGB India and Lanka IOC to provide Maritime Support Services • Retains interest in Courier and the Freight Forwarding industry 26
  • 27. Transportation: 10-11 Update Turnover 4% Key Statistics 2010/11 2009/10 Growth Turnover (Rs. Mn) 734 664 11% Profit After Tax (Rs. Mn) 224 181 24% Sector Group • Growth in passenger sales drives sector performance during the year • GSA passenger and cargo sales have shown a growth of 38% and 21% respectively, year-on-year • Hemas was appointed as the GSA in Sri Lanka for Ukraine International Airlines during the year • Positive sentiment surrounding maritime industry contributes growth in Far Shipping sales • Far shipping operations expands to Chittagong , Bangladesh 27
  • 28. Transportation: Strategic Focus • Consolidate the market leadership position in the Aviation business • Look out for opportunities in the local aviation industry • Opportunities to expand the Maritime and Ports related business 28
  • 29. Leisure: Overview • Hemas owns 51% stake in Serendib Hotels, a public listed hotels group • Serendib Group consists 3 hotels located in Bentota, Negombo, Sigiriya, and manages and owns 19.9% of a fourth hotel in Kalutara with a room strength of 105 • Hemas owns 2 undeveloped properties in Kandy and Tangalle • Strategic alliance with Minor International, Thailand • Diethelm Travels, a strategic partnership with Diethelm Group, recently started operations in Maldives Kuchchaveli* Hotel Sigiriya, Sigiriya Hotel Mowbray, Dolphin, Kandy Waikkal Peace Haven, Serendib Tangalle Hotel, Bentota 29 Source: SLTDA *To be acquired
  • 30. Leisure: Market Statistics of Serendib Hotels Voting Non Voting Share Price Rs 30.80 Rs 18.70 Market Capitalization Rs 1.9Bn Rs 0.5Bn % of Total Market 0.07% 0.02% PER 16.0times 4.6times PBV 1.5times 0.5times No of Shares 60.4Mn 28.8Mn Public Shareholding 29.66% 26.64% 30
  • 31. Leisure: 10-11 Update Turnover 6% Key Statistics 2010/11 2009/10 Growth Turnover (Rs. Mn) 1035 752 38% Profit After Tax (Rs. Mn) 122 33 263% Sector Group • Our hotels continued to benefit from the positive outlook of the country • Hotels recorded an average occupancy in excess 80%, for the year under review • Dolphin Hotel was refurbished at a cost of Rs. 530Mn and reopened in October 2010 • Kani Lanka Resort and Spa was acquired by Hemas through Serendib Hotels PLC 31
  • 32. Leisure: Dolphin Hotel upgraded to 4 star • Reopened in October 2010 • Refurbishment cost - Rs. 530Mn 32
  • 33. Leisure : Twin Experience of PLAY & PAUSE at Dolphin . . . 33
  • 34. Leisure: Acquisition of Kani Lanka • A 150 key luxury hotel is being developed adjacent to the current hotel and will be the first – ever ‘Anantara‘ branded resort in Sri Lanka • Hemas acquired a 19.9% stake in Kani Lanka Resort and Spa, through its subsidiary Serendib Hotels PLC • Minor International PLC, our strategic partner, acquired the remaining 80.1% • The hotel is being managed by Serendib Leisure Management Limited 34
  • 35. Leisure: Strategic Focus • Refurbishment and repositioning of Hotel Serendib - construction to begin in May 2011 • Development of existing land banks, Peace Haven and Mowbray • Strategic investments with Minor to develop the Anantara brand 35
  • 36. Power: Overview • 100MW thermal power plant: a joint venture with a 10 year PPA expiring in 2014 • Hydro power plants with operational capacities of 2.0MW and 2.6MW • 2.4MW hydro power plant under construction • Hemas Power was listed in Sep 09, and Energy Demand Vs Generation Requirement raised Rs. 626Mn for new investments in Sri Lanka • Electricity demand to grow at a CAGR of 8.6% over the long-term in Sri Lanka • Long-Term Generation Plan of CEB estimates electricity demand to increase by 5,430MW by 2022 36
  • 37. Power: Key Statistics Share Price Rs 35.80 Market Capitalization Rs 4.5Bn % of Total Market 0.17 % PER 10.9 times PBV 1.3 times No of Shares 125Mn Public Shareholding 24.93% 10/11 09/10 Growth Group Turnover Rs 3.4Bn Rs 2.9Bn 19% Group Earnings Rs 426Mn Rs 244Mn 75% Shareholders’ Funds Rs 2.9Bn Rs 2.5Bn 17% Capital Employed Rs 4.4Bn Rs 3.7Bn 17% 37
  • 38. Power: 10-11 Update Turnover Key Statistics 2010/11 2009/10 Growth 19% Turnover (Rs. Mn) 3,412 2,867 19% Profit After Tax (Rs. Mn) 426 244 75% Sector Group • Heladhanavi continues to be the largest contributor to group profits • Hydro power contribution to sector profits grow to 45% in comparison to 25% in 09/10 • Sector finance costs show significant reduction due to refinancing of working capital at Heladhanavi • Hemas contributed ~ 7% to the national grid this year • Magal Ganga set to complete in September 2011 38
  • 39. Power: Strategic Focus • Development of on-going mini-hydro projects • Looking to enter non-conventional renewable energy space – Bio mass & wind energy • Explore overseas investments opportunities 39
  • 40. CSR: Hemas Outreach Foundation 40
  • 41. CSR: Our Objectives 1. Focus on Early Childhood Care and Development (ECCD) of young children through pre- schools 2. Training of pre-school teachers 3. Empower community led social development through island wide parental awareness programs 4. Improve children’s recreational facilities in disadvantaged communities 5. Improve child protection legislation and provide publicity for children’s issues 6. Sustaining the Menik Farm temporary preschools and play areas 41
  • 42. CSR: Our activities this year . . . • 33 Piyawara model pre-schools are being monitored and sustained by Hemas Outreach Foundation • Opened first ever model pre-school in the Northern Region in Jaffna in January 2011 • Set up pre-schools and play areas in post war relief villages in Vavuniya • Set up a special school for children with Down’s Syndrome in Hambantota area - 42 children are being rehabilitated • Conducted residential training programs for pre-school teachers • Weekly TV programme on Nugasevana to educate young mothers on early childhood development 42
  • 43. In conclusion . . . • All sectors in the Group are well placed to benefit from expected economic growth • Growth of the middle class segment to drive growth in FMCG and Healthcare industries • Major investments in the medium term to be in Hospitals, Hotels and Power • Exploring opportunities to enter new categories in the FMCG market 43
  • 44. Investor Relations Contact: Malinga Arsakularatne Chief Financial Officer +94 11 4731728 / +94 77 2233642 malinga@hemas.com CONFIDENTIALITY AGREEMENT: Any confidentiality information disclosed in this presentation shall be used by the receiving party exclusively for the purposes of fulfilling the receiving party’s obligation and for no other purpose except with the consent of the disclosing party. 44